3. Umbruch 4.4..2005 - Online Pot

104 J. Fernández-Ruiz et al.
61 Adams IB, Martin BR (1996) Cannabis: pharmacology and toxicology in animals and humans.
Addiction 91: 1585–1614
62 Bisogno T, Hanusˇ L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB,
Mechoulam R, Di Marzo V (2001) Molecular targets for cannabidiol and its synthetic analogues:
effects on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide.
Brit J Pharmacol 134: 845–852
63 Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some pharmacological
aspects. J Clin Pharmacol 42: 11S–19S
64 Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J (2005)
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro:
Relevance to Parkinson’s disease. Neurobiol Dis; in press
65 Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernández-Ruiz JJ, Brouillet E (2004) Potential
involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo: implication for
Huntington’s disease. Neuroreport 15: 2375–2379
66 Reddy PH, Williams M, Tagle DA (1999) Recent advances in understanding the pathogenesis of
Huntington’s disease. Trends Neurosci 22: 248–255
67 Liu B, Hong JS (2003) Role of microglia in inflammation-mediated neurodegenerative diseases:
mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304: 1–7
68 Walter L, Stella N (2004) Cannabinoids and neuroinflammation. Br J Pharmacol 141: 775–785
69 Aloisi F (1999) The role of microglia and astrocytes in CNS immune surveillance and
immunopathology. Adv Exp Med Biol 468: 123–133
70 Iadecola C, Alexander M (2001) Cerebral ischemia and inflammation. Curr Opin Neurol 14:
89–94
71 Dusart I, Schwab ME (1994) Secondary cell death and the inflammatory reaction after dorsal
hemisection of the rat spinal cord. Eur J Neurosci 6: 712–724
72 McGeer PL, Yasojima K, McGeer EG (2001) Inflammation in Parkinson’s disease. Adv Neurol 86:
83–89
73 Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide PG, Vonsattel JP,
DiFiglia M (2001) Early and progressive accumulation of reactive microglia in the Huntington
disease brain. J Neuropathol Exp Neurol 60: 161–172
74 McGeer PL, Rogers J (1992) Anti-inflammatory agents as a therapeutic approach to Alzheimer’s
disease. Neurology 42: 447–449
75 Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, Williams A
(2002) Neuroinflammation in Alzheimer’s disease and prion disease. Glia 40: 232–239
76 Baker D, Pryce G (2003) The therapeutic potential of cannabis in multiple sclerosis. Expert Opin
Investig Drugs 12: 561–567
77 Gómez Del Pulgar T, De Ceballos ML, Guzman M, Velasco G (2002) Cannabinoids protect astrocytes
from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase
B pathway. J Biol Chem 277: 36527–36533
78 Molina-Holgado E, Vela JM, Arevalo-Martin A, Almazan G, Molina-Holgado F, Borrell J, Guaza
C (2002) Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid
receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 22: 9742–9753
79 Smith SR, Terminelli C, Denhardt G (2000) Effects of cannabinoid receptor agonist and antagonist
ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in
endotoxemic mice. J Pharmacol Exp Ther 293: 136–150
80 Klein TW, Lane B, Newton CA, Friedman H (2000) The cannabinoid system and cytokine network.
Proc Soc Exp Biol Med 225: 1–8
81 Puffenbarger RA, Boothe AC, Cabral GA (2000) Cannabinoids inhibit LPS-inducible cytokine
mRNA expression in rat microglial cells. Glia 29: 58–69
82 Waksman Y, Olson JM, Carlisle SJ, Cabral GA (1999) The central cannabinoid receptor (CB1)
mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 288:
1357–1366
83 Molina-Holgado F, Lledo A, Guaza C (1997) Anandamide suppresses nitric oxide and TNF-alpha
responses to Theiler’s virus or endotoxin in astrocytes. Neuroreport 8: 1929–1933
84 Hillard CJ, Muthian S, Kearn CS (1999) Effects of CB(1) cannabinoid receptor activation on cerebellar
granule cell nitric oxide synthase activity. FEBS Lett 459: 277–281
85 Coffey RG, Snella E, Johnson K, Pross S (1996) Inhibition of macrophage nitric oxide production
by tetrahydrocannabinol in vivo and in vitro. Int J Immunopharmacol 18: 749–752